The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease. Some non-specific biomarkers have been proposed (Neurofilaments, TDP-43) but their diagnostic value remains controversial. This study aims to identify ALS-specific platelet biomarkers using targeted and untargeted multi-omic approaches, in order to enable differential diagnosis between ALS and other motor neuron diseases.
Men or women aged 18 to 75
ALS diagnosed according to the El Escorial criteria
ALS diagnosis less than 3 months ago
Onset of symptoms defined as the time when muscle weakness was first observed by the patient less than 2 years ago
Genetic variants associated with ALS
Pregnant or breastfeeding women
Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day)
Uncontrolled diabetes